Literature DB >> 16889866

Stable cationic microparticles for enhanced model antigen delivery to dendritic cells.

Christian Wischke1, Hans-Hubert Borchert, Julian Zimmermann, Ingo Siebenbrodt, Dirk R Lorenzen.   

Abstract

The objectives of this work were (i) to prepare physically stable cationic microparticles and (ii) to study the impact of the surface properties on microparticle phagocytosis and the phenotype of dendritic cells (DC). Protein loaded biodegradable microparticles from poly(lactic-co-glycolic acid) [PLGA] were produced in a micromixer-based w/o/w solvent evaporation procedure. Anionic particles were obtained by using polyvinyl alcohol (PVA) as stabilizing agent; for cationic surfaces cetyltrimethylammonium bromide (CTAB) and chitosan/PVA or DEAE-dextran/PVA blends were evaluated. In phagocytosis studies human monocytes and monocyte-derived DC were incubated with microparticles and analysed by flow cytometry. While CTAB modified microparticles lost their positive charge and aggregated due to CTAB desorption from the particle surface, the modification with chitosan and DEAE-dextran resulted in stable microparticles without cell toxicity. Due to a very low endotoxin content, phagocytosis of anionic and cationic microparticles did not induce an upregulation of maturation-associated surface markers on DC. DEAE-dextran modified microparticles showed an enhanced model protein delivery into phagocytic cells. Overall, PLGA microparticles are suitable vehicles for protein delivery to DC, which might be used for DC-based cell therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889866     DOI: 10.1016/j.jconrel.2006.06.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine.

Authors:  Jeremy S Blum; W Mark Saltzman
Journal:  J Control Release       Date:  2008-04-16       Impact factor: 9.776

Review 2.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

3.  Presentation Modality of Glycoconjugates Modulates Dendritic Cell Phenotype.

Authors:  N A Hotaling; D M Ratner; R D Cummings; J E Babensee
Journal:  Biomater Sci       Date:  2014-10-01       Impact factor: 6.843

Review 4.  Nanomedicine based approaches for combating viral infections.

Authors:  Saurabh Shah; Mahavir Bhupal Chougule; Arun K Kotha; Rama Kashikar; Chandraiah Godugu; Rajeev Singh Raghuvanshi; Shashi Bala Singh; Saurabh Srivastava
Journal:  J Control Release       Date:  2021-08-08       Impact factor: 11.467

5.  Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins.

Authors:  Laura J Peek; Lydia Roberts; Cory Berkland
Journal:  Langmuir       Date:  2008-08-05       Impact factor: 3.882

6.  Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA.

Authors:  Ashwin Basarkar; Dilip Devineni; Ravi Palaniappan; Jagdish Singh
Journal:  Int J Pharm       Date:  2007-05-18       Impact factor: 5.875

Review 7.  Nanomaterials for cancer immunotherapy.

Authors:  Wantong Song; Sara N Musetti; Leaf Huang
Journal:  Biomaterials       Date:  2017-09-17       Impact factor: 12.479

8.  Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against Leishmania in hamsters by inducing Th1-type immune responses.

Authors:  S Kansal; R Tandon; A Verma; P Misra; A K Choudhary; R Verma; P R P Verma; A Dube; P R Mishra
Journal:  Br J Pharmacol       Date:  2014-07-25       Impact factor: 8.739

9.  Delivery of rapamycin to dendritic cells using degradable microparticles.

Authors:  S Jhunjhunwala; G Raimondi; A W Thomson; S R Little
Journal:  J Control Release       Date:  2008-10-26       Impact factor: 9.776

10.  Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.

Authors:  Mauricio A Arias; Andrew Loxley; Christy Eatmon; Griet Van Roey; David Fairhurst; Mark Mitchnick; Philip Dash; Tom Cole; Frank Wegmann; Quentin Sattentau; Robin Shattock
Journal:  Vaccine       Date:  2010-12-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.